Last updated: March 5, 2026
What is the drug identified by NDC 64380-0170?
NDC 64380-0170 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody designed for targeted treatment of relapsed or refractory multiple myeloma. Approved by the FDA in August 2020, it is marketed by GlaxoSmithKline (GSK) (FDA, 2020).
Market Landscape
Patient Population
The drug targets relapsed or refractory multiple myeloma (RRMM):
- Estimated eligible patient base in the U.S.: approximately 34,000 diagnosed cases annually.
- Refractory cases after proteasome inhibitors and immunomodulatory drugs: roughly 20,000 patients.
- Patients who are transplant-ineligible or unresponsive to existing therapies: approximately 12,000–15,000.
Treatment Landscape
- Multiple myeloma therapies include lenalidomide, pomalidomide, carfilzomib, daratumumab.
- Belantamab mafodotin is positioned as a myeloma "third-line" or "later-line" therapy.
- Competition from drugs such as selinexor, idecabtagene vicleucel (ide-cel), and CAR-T therapies.
Market Trends
- Growing prevalence of multiple myeloma driven by aging populations.
- Increasing adoption of targeted therapies like antibody-drug conjugates.
- The global multiple myeloma drug market forecast at CAGR of 9.4% from 2022 to 2027 (Fortune Business Insights, 2022).
Commercial Dynamics
Revenue Estimates
- 2022 global sales: approximately $380 million.
- U.S. market share: 70-75%, driven by FDA approval and reimbursement policies.
- Revenue growth driven by increasing use in late-line treatment, with potential expansion into earlier lines.
Pricing History and Projections
- Initial U.S. list price: around $8,600 per 30 mg dose.
- Typical dosage: 2.5 mg/kg every 3 weeks (up to 3 doses per cycle).
- Estimated average annual treatment cost per patient: approximately $152,000.
Price Adjustments
- Most drug prices in the multiple myeloma space have experienced 4-6% annual increases, factoring inflation, manufacturing, and R&D costs (IQVIA, 2023).
- Varying reimbursement policies may influence net prices downward by 10-15%.
Future Price Projections
| Year |
Estimated Average Price per Patient |
Key Drivers |
| 2023 |
$152,000 |
Stabilization post-launch; payer negotiations |
| 2024 |
$157,500 |
Moderate price increase, driven by inflation and demand |
| 2025 |
$163,750 |
Increased competition from newer agents; pipeline developments |
| 2026 |
$170,000 |
Potential specialty pricing adjustments, expanded indications |
Note: Price projections assume no major regulatory or policy changes impacting drug pricing.
Reimbursement Scenario
- Medicare and private insurers typically reimburse around 80-90% of the list price.
- Discounts and patient assistance programs could lower out-of-pocket costs.
- Code 96413 (for infusions) or specific billing codes influence reimbursement levels.
Risks to Market and Pricing
- Emergence of novel therapies with superior efficacy or safety profiles.
- Enhanced biosimilar or generic competition within 5-7 years of patent expiry.
- Changes in healthcare policy targeting drug price regulation and cost containment.
Patent and Regulatory Timeline
- Patent protections extend into 2030.
- FDA approval for potential new indications or combination regimens could expand market reach.
- Ongoing Phase 3 trials assessing earlier-line use may influence future pricing strategies.
Summary
The current market for belantamab mafodotin favors continued revenue growth driven by expanding indications and broader access. Price increases will likely follow inflation trends, with primary uncertainty stemming from competitive dynamics and regulatory shifts.
Key Takeaways
- NDC 64380-0170 (Blenrep) is a key player in the late-line multiple myeloma market with annual revenues of circa $380 million.
- The U.S. remains the dominant market, with prices around $152,000 per patient annually.
- Projections suggest steady price increases of 3-4%, contingent on competitive pressures and pipeline developments.
- Future market expansion depends on approval for earlier-line treatments and combination strategies.
- Price regulation and biosimilar entry could compress margins within the next 5-7 years.
FAQs
1. How does the price of Blenrep compare to other multiple myeloma therapies?
Blenrep’s annual cost (~$152,000) is comparable to other antibody-based therapies like daratumumab, but generally higher than immunomodulators such as lenalidomide (~$70,000/year).
2. What are the main factors influencing its future price?
Market competition, patient demand, pipeline advancements, regulatory changes, and reimbursement policies.
3. Are there upcoming patents or exclusivities that may impact pricing?
Patents extend into 2030; exclusivity is unlikely to expire before then, maintaining market control.
4. Could biosimilars enter the market, and when?
Potential biosimilar development could occur after patent expiry, possibly 5–7 years from now.
5. How has COVID-19 affected the market and pricing strategies for this drug?
Pandemic-related healthcare disruptions have delayed clinical access and introduction of new therapies but have not significantly altered existing pricing trajectories.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves Blenrep for multiple myeloma.
[2] Fortune Business Insights. (2022). Global Multiple Myeloma Drug Market Report.
[3] IQVIA. (2023). The Impact of Inflation on Biopharmaceutical Pricing.
